Summit, N.J., November 20, 2014 – Continually striving to provide customers with the tools needed to maintain healthy, productive pigs, Merck Animal Health has developed a new online resource for producers. The tool is designed to help them better understand the factors that can influence vaccination protocol decision making.
“Having a solid knowledge of vaccination best practices and vaccine options can be beneficial when discussing protocols with your veterinarian – helping to ensure that the decisions you are making are the best ones for your herd,” says Jack Creel, D.V.M., Merck Animal Health senior swine technical services manager. “We feel it’s important that our customers have access to all necessary information so they can make the right, science-based decisions for their animals.”
Using the decision tree tool, producers answer a series of operation-specific questions, including types of weaning facilities, disease challenges, preferences of vaccination timing and frequency, and the history of the herds’ immune system responses. Based on the confidential information submitted and the individual needs of that operation, the program generates a suggested vaccination protocol, which the producer can discuss with the veterinarian. In addition, a recommendation for a Circumvent G2 product that fits within the suggested protocol is provided.
“This tool helps streamline the decision making that goes into formulating the most effective vaccination plan,” says Dr. Creel. “By simplifying the process, producers can work more efficiently with their veterinarian and focus their valuable time and attention on other areas of the business.”
The vaccines can be administered to pigs as early as 3 days of age, and producers can vaccinate with Circumvent PCV G2 or Circumvent PCV-M G2, depending on whether or not the herd has been exposed to Mycoplasma hyopneumoniae. Once the most appropriate vaccine is chosen, producers consider the timing and frequency options that will work best. For some, vaccinating once may be the most convenient, while others may prefer the two-dose option for greater protection due to added disease pressure. Regardless of the suggested protocol, Circumvent G2 offers a five-month duration of immunity (DOI), giving pigs longer lasting protection.
Learn more about how the Circumvent G2 decision tree tool can assist in determining the best vaccination option for your operation at www.circumvent-g2.com.
About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn and Twitter at @MerckAH.
Merck Forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in MSD’s 2013 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).